What was the market valuation of the US fungal endocarditis market in 2024?

The market valuation was $76.49 Million in 2024. Read More

What is the projected market valuation for the US fungal endocarditis market by 2035?

The projected valuation for 2035 is $140.0 Million. Read More

What is the expected CAGR for the US fungal endocarditis market during the forecast period 2025 - 2035?

The expected CAGR during this period is 5.65%. Read More

Which companies are considered key players in the US fungal endocarditis market?

Key players include Pfizer Inc, Merck & Co Inc, Astellas Pharma Inc, Gilead Sciences Inc, Bristol-Myers Squibb Company, Novartis AG, Roche Holding AG, and AbbVie Inc. Read More

What are the main treatment options available in the US fungal endocarditis market?

Main treatment options include antifungal medication, surgery, and combined treatment, with antifungal medication valued at $45.0 - $80.0 Million. Read More

How do the different types of fungal species impact the market valuation?

Candida species, Aspergillus species, and Histoplasma capsulatum have respective valuations of $30.0 - $55.0 Million, $25.0 - $45.0 Million, and $21.49 - $40.0 Million. Read More

What diagnostic methods are utilized in the US fungal endocarditis market?

Diagnostic methods include physical examination, blood tests, X-ray, echocardiography, and electrocardiogram, with echocardiography valued at $20.0 - $40.0 Million. Read More

What is the distribution of end-users in the US fungal endocarditis market?

End-users include hospitals, clinics, diagnostic centers, and others, with hospitals valued at $30.0 - $55.0 Million. Read More

How does the market for antifungal medication compare to other treatment options?

Antifungal medication leads the market with a valuation of $45.0 - $80.0 Million, significantly higher than surgery and combined treatment. Read More

What trends are anticipated in the US fungal endocarditis market over the next decade?

The market is expected to grow steadily, reaching $140.0 Million by 2035, driven by advancements in treatment and diagnostics. Read More

US Fungal Endocarditis Market

ID: MRFR/LS/17824-HCR

100 Pages

Vikita Thakur

Last Updated: April 06, 2026

US Fungal Endocarditis Market Research Report By Type (Candida species, Aspergillus species, Histoplasma capsulatum), By Diagnosis (physical examination, blood test, X-ray, echocardiography, electrocardiogram), By Treatment (antifungal medication, surgery, combined treatment, voriconazole, amphotericin B (AMB), itraconazole, caspofungin, echinocandins, others) and By End User (hospital, clinics, diagnostic centers, others) - Growth & Industry Forecast 2025 To 2035

US Fungal Endocarditis Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Food, Beverages & Nutrition, BY Type (USD Million)
  1. 4.1.1 Candida species
  2. 4.1.2 Aspergillus species
  3. 4.1.3 Histoplasma capsulatum
2. 4.2 Food, Beverages & Nutrition, BY Diagnosis (USD Million)
  1. 4.2.1 Physical examination
  2. 4.2.2 Blood test
  3. 4.2.3 X-ray
  4. 4.2.4 Echocardiography
  5. 4.2.5 Electrocardiogram
3. 4.3 Food, Beverages & Nutrition, BY Treatment (USD Million)
  1. 4.3.1 Antifungal medication
  2. 4.3.2 Surgery
  3. 4.3.3 Combined treatment
4. 4.4 Food, Beverages & Nutrition, BY End-User (USD Million)
  1. 4.4.1 Hospital
  2. 4.4.2 Clinics
  3. 4.4.3 Diagnostic centers
  4. 4.4.4 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck & Co Inc (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Astellas Pharma Inc (JP)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Gilead Sciences Inc (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Bristol-Myers Squibb Company (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Novartis AG (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Roche Holding AG (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AbbVie Inc (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY DIAGNOSIS
4. 6.4 US MARKET ANALYSIS BY TREATMENT
5. 6.5 US MARKET ANALYSIS BY END-USER
6. 6.6 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
9. 6.9 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
11. 6.11 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
12. 6.12 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 (% SHARE)
13. 6.13 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 FOOD, BEVERAGES & NUTRITION, BY DIAGNOSIS, 2024 (% SHARE)
15. 6.15 FOOD, BEVERAGES & NUTRITION, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
16. 6.16 FOOD, BEVERAGES & NUTRITION, BY TREATMENT, 2024 (% SHARE)
17. 6.17 FOOD, BEVERAGES & NUTRITION, BY TREATMENT, 2024 TO 2035 (USD Million)
18. 6.18 FOOD, BEVERAGES & NUTRITION, BY END-USER, 2024 (% SHARE)
19. 6.19 FOOD, BEVERAGES & NUTRITION, BY END-USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million)
  3. 7.2.3 BY TREATMENT, 2025-2035 (USD Million)
  4. 7.2.4 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Food, Beverages & Nutrition Market Segmentation

Food, Beverages & Nutrition By Type (USD Million, 2025-2035)

Candida species
Aspergillus species
Histoplasma capsulatum

Food, Beverages & Nutrition By Diagnosis (USD Million, 2025-2035)

Physical examination
Blood test
X-ray
Echocardiography
Electrocardiogram

Food, Beverages & Nutrition By Treatment (USD Million, 2025-2035)

Antifungal medication
Surgery
Combined treatment

Food, Beverages & Nutrition By End-User (USD Million, 2025-2035)

Hospital
Clinics
Diagnostic centers
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”